Zobrazeno 1 - 10
of 30
pro vyhledávání: '"William B. Fisher"'
Autor:
Ryan D. Gentzler, Ahad Ali Sadiq, Goetz H. Kloecker, Robert M. Langdon, Shadia I. Jalal, Karen L. Reckamp, Sandra K. Althouse, Greg Andrew Durm, Salma K. Jabbour, Nikhil Shukla, Nasser H. Hanna, Bamidele Adesunloye, Robin Zon, William B. Fisher, Ebenezer A. Kio
Publikováno v:
Journal of Clinical Oncology. 38:9032-9032
9032 Background: Consolidation checkpoint inhibitor therapy (CPI) for up to 1 year following chemoradiation (CRT) is a current standard of care for pts with inoperable stage III NSCLC. However, some pts are not able to complete 1 year of CPI due to i
Autor:
Ramaswamy Govindan, Rafat Ansari, Menggang Yu, A. K. Agarwala, William B. Fisher, Shadia I. Jalal, Marcus A. Neubauer, Donald A. Richards, Nasser H. Hanna, Cynthia S. Johnson, D. Bruetman, Lawrence H. Einhorn, Timothy Breen, Anton Melnyk, H. D. Riggs
Publikováno v:
Annals of Oncology. 23:1730-1738
Background Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). Consolidation docetaxel (D; Taxotere) after EP/XRT resulted in increased
Autor:
Ebenezer A. Kio, Ahad Ali Sadiq, Robin Zon, B. Adesunloye, Ryan D. Gentzler, Shadia I. Jalal, Salma K. Jabbour, G. Durm, Robert M. Langdon, William B. Fisher, Karen L. Reckamp, Sandra Althouse, Nasser H. Hanna, Goetz H. Kloecker
Publikováno v:
Journal of Thoracic Oncology. 13:S321
Autor:
William B. Fisher, Robert M. Langdon, Ahad Ali Sadiq, Robin Zon, Goetz H. Kloecker, Ryan D. Gentzler, Ebenezer A. Kio, Shadia I. Jalal, Bamidele Adesunloye, Karen L. Reckamp, Salma K. Jabbour, Greg Andrew Durm, Sandra K. Althouse, Nasser H. Hanna
Publikováno v:
Journal of Clinical Oncology. 36:8500-8500
8500Background: Concurrent chemoradiation (CRT) has been the standard Rx for pts with unresectable stage III NSCLC. A recent phase III trial (PACIFIC) of consolidation durvalumab [PDL-1 inhibitor] ...
Autor:
Rafat Abonour, Constantin T. Yiannoutsos, Lisa L. Wood, Rafat Ansari, William B. Fisher, Attaya Suvannasankha, Beth E. Juliar, Gina G. Smith, Larry D. Cripe, Christopher A. Fausel
Publikováno v:
The Oncologist. 12:99-106
Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy inhibit angiogenesis. The synergy of such a combination may decrease toxicity while maintaining efficacy. The Hoosier Oncology
Autor:
Jianzhao Shen, Alan B. Sandler, Nasser H. Hanna, William B. Fisher, Sin-Ho Jung, Rafat Ansari
Publikováno v:
Lung Cancer. 35:293-297
Results of a previous Hoosier Oncology Group (HOG) study revealed a small survival advantage for VIP versus etoposide and cisplatin (EP) for patients with extensive stage small cell lung cancer (SCLC). This phase II study evaluated VIP with concurren
Autor:
Cynthia D. Johnson, Greg Andrew Durm, Karen L. Reckamp, Salma K. Jabbour, Nasser H. Hanna, Goetz H. Kloecker, Ahad Ali Sadiq, Shadia I. Jalal, Robin Zon, William B. Fisher
Publikováno v:
Journal of Clinical Oncology. 35:8523-8523
8523 Background: The standard of care for unresectable stage III NSCLC is concurrent chemorad. Following treatment, the risk of radiation pneumonitis is greatest at 1-3 mo. Pneumonitis risk increases with consolidation chemotherapy. A previous trial
Autor:
Nasser H. Hanna, Michael L. Titzer, William B. Fisher, Ebenezer A. Kio, Salma K Jabbour, Ziyue Liu, T. Breen, Greg Andrew Durm
Publikováno v:
Journal of Clinical Oncology. 34:e20025-e20025
e20025Background: A standard of care for pts with inoperable or unresectable stage III NSCLC is concurrent chemoradiation alone, but approximately 80% of pts will develop recurrent or metastatic di...
Publikováno v:
American Journal of Clinical Oncology. 14:412-415
Fifty-one patients with advanced non-small-cell lung cancer were treated on a Hoosier Oncology Group protocol with an aggressive, high-dose cisplatin combination chemotherapy regimen. All patients had a Karnofsky performance status of 80% or higher a